AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 81 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,828,982 | +55.3% | 4,059,894 | 0.0% | 0.10% | +96.0% |
| Q1 2023 | $1,177,369 | -35.5% | 4,059,894 | 0.0% | 0.05% | -35.1% |
| Q4 2022 | $1,826,546 | -14.5% | 4,059,894 | 0.0% | 0.08% | -13.5% |
| Q3 2022 | $2,136,000 | +4.1% | 4,059,894 | 0.0% | 0.09% | +14.1% |
| Q2 2022 | $2,051,000 | -78.0% | 4,059,894 | 0.0% | 0.08% | -72.6% |
| Q1 2022 | $9,338,000 | -23.5% | 4,059,894 | +57.9% | 0.28% | +20.8% |
| Q4 2021 | $12,212,000 | -28.8% | 2,571,000 | +19.2% | 0.24% | -18.3% |
| Q3 2021 | $17,154,000 | +17.7% | 2,157,727 | +3.0% | 0.29% | +32.6% |
| Q2 2021 | $14,575,000 | +34.6% | 2,094,100 | +53.2% | 0.22% | +36.2% |
| Q1 2021 | $10,827,000 | +81.3% | 1,367,073 | +80.2% | 0.16% | +88.2% |
| Q4 2020 | $5,971,000 | +59.2% | 758,739 | +43.4% | 0.08% | +25.0% |
| Q3 2020 | $3,751,000 | +243.8% | 529,100 | +348.7% | 0.07% | +195.7% |
| Q2 2020 | $1,091,000 | – | 117,929 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |